TX HB 3785
deadRelating to labeling requirements for compounded drug products.
Texas · 89th Legislature (2025 Regular Session) · lower
Quick answers
Did TX HB 3785 pass?
No. TX HB 3785 did not pass — it was defeated or died in the legislative process (2025-04-28). Latest recorded action (2025-04-28): Failed to receive affirmative vote in comm.
What is TX HB 3785 about?
TX HB 3785 is a bill in the 89th Legislature (2025 Regular Session) titled “Relating to labeling requirements for compounded drug products.”.
Who sponsors TX HB 3785?
Gervin-Hawkins is the primary sponsor of TX HB 3785.
- Introduced
- 2025-03-26
- Latest action
- 2025-04-28 — Failed to receive affirmative vote in comm.
- Bill type
- bill
- Last updated
- —
Subjects
Sponsors
- Gervin-Hawkinsprimary
Committees
Not provided by source.
Action timeline
2025-03-05
Filed
filing
2025-03-26
Read first time
introduction,reading-1
2025-03-26
Referred to Public Health
referral-committee
2025-04-14
Considered in public hearing
2025-04-14
Testimony taken/registration(s) recorded in committee
2025-04-14
Left pending in committee
2025-04-28
Considered in public hearing
2025-04-28
Committee substitute considered in committee
substitution
2025-04-28
Failed to receive affirmative vote in comm.
committee-failure
Versions
Documents
Votes
Not provided by source.
Related bills
No related bills recorded for this bill.
Official source
Attribution
Data from openstates_bulk_csv, retrieved 2026-07-24T05:33:51.767464Z
Inspect retained evidence for changes recorded after evidence tracking began:
Session-wide evidence can include changes to other bills:
Use this data
Every field on this page is available from the free public API — no key or licence required. Fetch this bill as JSON: GET /api/v1/bills?jurisdiction=TX&identifier=HB 3785. See the API docs or the MCP server for AI assistants.
Known limitations
- Sponsor party and chamber affiliation are not yet captured by this API.
- Committee referrals are not yet captured.
See the methodology page for data sources and limitations.